Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Christos Damaskos,Iason Psilopatis,Anna Garmpi,Dimitrios Dimitroulis,Konstantinos Nikolettos,Kleio Vrettou,Panagiotis Sarantis,Evangelos Koustas,Gregory Kouraklis,Efstathios A. Antoniou,Michail V. Karamouzis,Nikos Nikolettos,Panagiotis Tsikouras,Georgios Marinos,Emmanouil Kontomanolis,Konstantinos Kontzoglou,Nikolaos Garmpis
DOI: https://doi.org/10.3390/cancers16010209
2024-01-02
Cancers
Abstract:Background/Aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer. Materials and Methods: A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients. Results: Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer. Conclusions: High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.
oncology
What problem does this paper attempt to address?